DAFNA Capital Management’s Cogent Biosciences COGT Stock Holding History

DAFNA Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-223,554	Closed	-$1.67M	–	92
2022 Q1	$1.67M	Hold	223,554	–	–	0.44%	55
2021 Q4	$1.92M	Hold	223,554	–	–	0.48%	44
2021 Q3	$1.88M	Hold	223,554	–	–	0.5%	51
2021 Q2	$1.81M	Hold	223,554	–	–	0.38%	51
2021 Q1	$1.96M	Buy	+223,554	New	+$2.15M	0.47%	51
2018 Q2	–	Sell	-1,975	Closed	-$88K	–	77
2018 Q1	$88K	Buy	+1,975	New	+$87.8K	0.04%	73

Other funds holding COGT

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DAFNA Capital Management's COGT Position: Q2 2022 in Review

DAFNA Capital Management sold out of Cogent Biosciences (COGT) in Q2 2022, closing a stake of 223,554 shares — an estimated $1.67M sold.

DAFNA Capital Management first reported a position in COGT in Q1 2018 and held it in 6 quarters. The position peaked at $1.96M in Q1 2021. 112 funds tracked by Wall St. Rank hold COGT as of Q2 2022.

DAFNA Capital Management reported no remaining Cogent Biosciences position as of Q2 2022 after selling out during the quarter.
DAFNA Capital Management sold 223,554 Cogent Biosciences shares in Q2 2022, an estimated $1.67M.
DAFNA Capital Management first reported a position in Cogent Biosciences in Q1 2018 and held it in 6 quarters.
DAFNA Capital Management's Cogent Biosciences position peaked at $1.96M in Q1 2021.
112 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2022.

Based on DAFNA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.